# Thymosin Alpha-1 Benefits Reported in Research > Thymosin Alpha-1 benefits reported in research: hepatitis B response, immune reconstitution, vaccine support, and the honest limits of the evidence — including the null sepsis trial. Cited. What the studies actually report Thymosin Alpha-1 can do — graded by how strong the evidence is, with the limits stated as plainly as the benefits. ## The short version The Thymosin Alpha-1 benefits with the strongest support are immune ones, and they are setting-dependent. The clearest is in chronic hepatitis B: adding it to antiviral drugs helped more patients clear a key viral marker. It has also helped rebuild immune cells in people with HIV, improved vaccine responses in patients with weak immune systems, and supported recovery after stem-cell transplants — all real, but from smaller or less rigorous studies. As an immune modulator it is generally well tolerated, with mild injection-site reactions the main downside. The honest limits matter just as much: the largest, best-run sepsis trial found no benefit, COVID-19 results are mixed, and it is not FDA-approved in the US. Every claim below is tied to the study that measured it, in the population and dose it was tested at. ## The best-supported benefit: chronic hepatitis B response The most reproducible Thymosin Alpha-1 benefit is in chronic hepatitis B. Across a meta-analysis of eight trials and 583 patients, combining Thymosin Alpha-1 with lamivudine was significantly superior to lamivudine alone for hepatitis B e-antigen seroconversion — 45.1% versus 15.2% (P<0.00001) — and for virological response, with Tα1 plus entecavir also outperforming entecavir alone in cirrhotic patients [13]. A separate meta-analysis found combination therapy achieved higher virological response and reduced viral breakthrough [12]. These are human endpoints in randomized settings, which is why hepatitis B is the strongest-graded benefit in the record. ## Immune reconstitution and vaccine support Thymosin Alpha-1 has been studied for rebuilding immunity. In an HIV pilot study, 12 weeks of treatment increased sjTREC levels (a marker of new immune-cell output) versus controls [8], and a 2024 study in immunological non-responders living with HIV reported the CD4+ T-cell proportion rising from 17.2% to 29.1% (P<0.001) with reduced T-cell exhaustion [15]. After haploidentical stem-cell transplantation, Tα1 was associated with reduced viral reactivation and improved T-cell reconstitution [9]. And in immunosuppressed hemodialysis patients, adding Tα1 to an adjuvanted pandemic H1N1 vaccine improved seroconversion enough to meet licensing immunogenicity criteria [11]. These benefits are real but come from smaller, often non-blinded studies. ## The honest limits of the benefit claims The limits deserve equal billing. The largest, most rigorous sepsis trial — phase-3 TESTS, 1,106 adults — found no significant 28-day mortality benefit (hazard ratio 0.99, P=0.93) [3], tempering the marginally positive earlier ETASS result (26.0% vs 35.0%) [2]. In COVID-19, a retrospective cohort reported lower mortality (11.11% vs 30.00%) [6], but a 2022 systematic review of about 5,300 patients found no statistically significant overall benefit. Much of the positive trial base is single-region, open-label, or small, and meta-analyses repeatedly flag moderate-to-high risk of bias. None of these benefits is established for personal use, and the compound is not FDA-approved in the US. ## Why these benefits are biologically plausible The reported immune benefits line up with a well-characterized mechanism, which is part of why the strongest signals are taken seriously rather than dismissed. Thymosin Alpha-1 matures dendritic cells through Toll-like receptors (TLR2/TLR9), pushing T-cells toward a Th1, cell-mediated response, while an IDO-dependent arm generates regulatory T cells that keep the response balanced [5]. In practical terms, that dual action can restore effector immunity where it has been lost — reversing T-cell exhaustion (lowering PD-1 and Tim-3) and rebuilding depleted T-cell populations, as reported in severe COVID-19 [6] and in immunological non-responders living with HIV [15]. So the benefit claims with the best support — viral clearance in hepatitis B, immune reconstitution, better vaccine responses — are not random observations; they are downstream of a mechanism that has been mapped in human and mouse cells. That biological plausibility does not turn an unconfirmed signal into a proven outcome, but it is why the hepatitis B and immune-reconstitution data are graded as the strongest in the record. ## Thymosin alpha 1 bodybuilding Thymosin alpha 1 bodybuilding claims are not supported by the evidence. Thymosin Alpha-1 is an immunomodulatory peptide — it adjusts immune-cell behavior through dendritic cells and T-cells [5] — not an anabolic, growth, or performance peptide. There is no evidence in the published literature that it builds muscle, increases strength, or enhances athletic performance, and it does not act on growth-hormone or muscle-protein pathways. People sometimes confuse it with thymosin beta-4 / TB-500 (a different, tissue-repair peptide that is on the WADA Prohibited List), but even that is a repair peptide, not a muscle-builder. The benefits on record for Thymosin Alpha-1 are immunological, not anabolic. --- A titration reading of the Thymosin Alpha-1 (thymalfasin) record — the thymic immunomodulator's strongest hepatitis-B signal logged first, the null phase-3 sepsis trial and the US non-approval held in plain sight, and the molecule kept ruled apart from thymosin beta-4, thymulin, and thymopentin; no clinic behind the rail and nothing here dosed, dispensed, or sold.